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Abstract
Previous studies identified prion protein (PrP) mutants which act as dominant negative inhibitors of prion formation
through a mechanism hypothesized to require an unidentified species-specific cofactor termed protein X. To study the
mechanism of dominant negative inhibition in vitro, we used recombinant PrP
C molecules expressed in Chinese hamster
ovary cells as substrates in serial protein misfolding cyclic amplification (sPMCA) reactions. Bioassays confirmed that the
products of these reactions are infectious. Using this system, we find that: (1) trans-dominant inhibition can be dissociated
from conversion activity, (2) dominant-negative inhibition of prion formation can be reconstituted in vitro using only
purified substrates, even when wild type (WT) PrP
C is pre-incubated with poly(A) RNA and PrP
Sc template, and (3) Q172R is
the only hamster PrP mutant tested that fails to convert into PrP
Sc and that can dominantly inhibit conversion of WT PrP at
sub-stoichiometric levels. These results refute the hypothesis that protein X is required to mediate dominant inhibition of
prion propagation, and suggest that PrP molecules compete for binding to a nascent seeding site on newly formed PrP
Sc
molecules, most likely through an epitope containing residue 172.
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Introduction
Prion diseases are fatal neurodegenerative diseases with
inherited, sporadic, and infectious etiologies [1–3]. The funda-
mental pathogenic event underlying prion diseases is generally
believed to be the misfolding of the normal, host-encoded cellular
prion protein (PrP
C) into a pathogenic conformer (PrP
Sc) [4],
although in some experiments discordances between PrP
Sc levels
and prion titers have been documented [5,6]. Mature PrP
C is a
,208 amino acid protein with a glycophosphatidyl inositol (GPI)
anchor, two N-linked carbohydrate groups, and a single disulfide
bond [7–10]. Experimentally, infectious prions can be formed de
novo from a minimal set of components (PrP, lipid, and polyanionic
molecules), which appear to form a high affinity physical complex
[11,12]. However, the precise mechanism by which PrP
Sc is
formed from the conformational conversion of PrP
C has yet to be
elucidated.
Studies examining the transmission of prions to transgenic mice
expressing human or mouse/human chimeric PrP led to the
hypothesis that a species-specific cofactor, termed protein X, is
required for PrP
Sc formation [13]. Utilizing a cell culture model of
prion formation, mouse (Mo) PrP single-point mutants that could
not undergo conformational conversion to form PrP
Sc were
identified [14–16]. These MoPrP mutants also acted in a
dominant negative manner in that they prevented the conversion
of wild type PrP
C when co-expressed in scrapie-infected cells. Two
of the residues identified as conferring this dominant negative
property correspond to naturally occurring polymorphic PrP
variants. Sheep expressing Q171R PrP and humans expressing
E219K PrP are both relatively resistant to prion infection [17–19],
although cases of prion disease have been reported in animals with
these genotypes [20–23]. In addition, substitution mutations to
basic amino acids at residues 171 and 214 in MoPrP also yield
dominant negative properties [14,16]. In mouse PrP
C, these four
residues, 167 (homologous to sheep PrP residue 171), 171, 214,
and 218, form a discontinuous epitope [24,25], which was
proposed to bind the protein X cofactor [14]. Hamster PrP
C
harbors a homologous putative binding site [26,27], and
transgenic mice expressing mouse and hamster PrP
C molecules
simultaneously are able to propagate both mouse and hamster
prions [28]. Pharmacological studies demonstrated that com-
pounds designed to bind to the putative protein X inhibit PrP
Sc
formation in scrapie-infected neuroblastoma cells [29]. However,
the protein X molecule has never been identified, and a recent
study showed that Q218K PrP molecules reduced the rate of
polymerization of wild type PrP molecules in a mixed polymer-
ization reaction containing bacterially expressed PrP substrates but
no additional cofactors [30]. Additionally, it has been shown that
other heterologous PrP molecules lacking mutations of the putative
protein X binding site can also interfere with conversion of
MoPrP
C to MoPrP
Sc in cell culture and biochemical assays [31–
33]. More broadly, the incubation periods of prion diseases appear
to be controlled by a complex and poorly understood relationship
between Prn-p, the gene encoding PrP, and prion strain [34,35].
For instance, in mice, some prion strains have shorter incubation
periods in mice expressing only the Prn-p(a) polymorphic allele
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cause disease faster in homozygous Prn-p(b/b) mice [36,37].
Additionally, some strains produce longer incubation periods in
Prn-p(a/b) heterozygote mice than in either homozygote [36]. In
another example, sheep with Q171R (a putative mutation of the
protein X binding site) mutant PrP alleles, previously thought to be
resistant to prion infection, are susceptible to bovine spongiform
encephalopathy as well as classical scrapie after long incubation
periods [20–23]. Within this context, it should be noted that the
bioassay experiments which originally supported the requirement
for protein X in prion propagation were performed with a limited
number of prion strains [13].
In this study, we use a combination of recently developed
techniques to investigate the mechanism of dominant negative
inhibition of prion formation in vitro. Specifically, we employ a
Chinese Hamster Ovary (CHO) cell stable expression system to
produce post-translationally processed PrP mutants, which can be
used as substrates for the serial protein misfolding cyclic
amplification (sPMCA) technique employing indirect sonication
[38] in reconstituted [39] and purified systems [11]. The sPMCA
technique has been used to generate infectious prions in vitro from
both crude brain homogenate and purified PrP
C preparations
[11,38,40]. Moreover, sPMCA experiments have shown that
polyanions can facilitate the formation of infectious prions de novo
in a completely prion-free environment [11]. In the present study,
we used sPMCA to convert CHO-expressed PrP
C substrate into
autocatalytic PrPres molecules, which were infectious to wild type
animals. We then tested whether dominant negative MoPrP
mutants and corresponding hamster (Ha) PrP mutants retain their
dominant negative properties in vitro. Surprisingly, we found that a
subset of hamster PrP mutants (T215K and Q219K) could be
converted into autocatalytic PrPres products in vitro. These mutant
PrP molecules also acted as trans-dominant inhibitors of both
CHO-expressed and brain-derived wild type PrP
C conversion in a
dose-dependent manner. Additionally, we found that pre-incubat-
ing wild type HaPrP
C substrate with either the scrapie template or
a polyanionic cofactor, which is required for conversion in our
purified system, did not prevent the inhibition of conversion by the
dominant negative mutant Q172R HaPrP. Interestingly, T215K
and Q219K HaPrPres could act as a seed to convert wild type
HaPrP
C, which indicates that PrP mutants physically interact with
wild type PrP
C. These results support a model in which dominant
negative PrP mutants inhibit prion formation through direct
interaction with a nascent seeding site on newly formed PrP
Sc
molecules as opposed to interaction with a cellular cofactor such as
protein X or with PrP
C molecules.
Materials and Methods
Animal welfare
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and the Dartmouth College IACUC committee
approved all animal work.
Generation of CHO PrP cell lines
Each CHO cell line stably expressing wild type or mutant PrP
was made separately by transfecting Flp-In
TM CHO cells with
pcDNA5/FRT/PrP plasmids using Lipofectamine
TM 2000.
Transfection and selection of polyclonal Flp-In
TM CHO cell lines
were carried out according to the manufacturer’s protocol. After
selection in hygromycin B, expression of PrP in each polyclonal
cell line was confirmed by Western blot analysis. Cells were
maintained at 37uC, 5% CO2, in Ham’s F12 media containing 1%
penicillin/streptomycin, 2 mM L-glutamine, and 10% fetal bovine
serum. The correct identity of all stably transfected, PrP-
expressing CHO cell lines used in this study was confirmed by
DNA extraction and sequencing.
Preparation of brain-derived and CHO-expressed PrP
substrates
All procedures were performed at 4uC. Brain-derived HaPrP
C
and CHO-expressed Q172R HaPrP was purified from hamster
brains as previously described except, after immunopurification,
the Q172R HaPrP was purified on a cobalt affinity column as
described below instead of an SP cation exchange column [11]. To
partially purify CHO-expressed PrP, each CHO cell line stably
expressing PrP was grown to confluence in 106150 mm dishes
(Corning). Cells were rinsed with ice-cold PBS and harvested on
ice with 10 ml lysis buffer [20 mM MOPS pH 7.0, 150 mM
NaCl, 1% Triton-X 100, 1% DOC plus Complete
TM EDTA-free
protease inhibitors (Roche)]. The lysate was Dounce homogenized
and allowed to solubilize on ice for 30 min. The solubilized lysate
was then subjected to ultracentrifugation at 100,0006g for 1 hr at
4uC and the supernatant was passed through a 0.2 mm syringe
filter (Millipore). The filtered supernatant was applied to a 2 ml
IMAC-CoCl2 column (GE Healthcare, Piscataway, NJ). The
column was washed with 10 ml of wash buffer [10 mM imidazole
(in MOPS pH 7.0, 150 mM NaCl), 1% Triton-X 100] and eluted
with 4 ml elution buffer [20 mM MES pH 6.4, 150 mM
imidazole (in MOPS pH 7.0, 150 mM NaCl), 150 mM NaCl,
1% Triton-X 100]. The eluted samples containing PrP were
divided into aliquots and stored at 270uC.
Preparation of PrP
Sc and PrP
0/0 mouse brain
homogenates
PrP
Sc was prepared separately from two hamster strains Sc237
and 139H and one mouse strain, RML. In order to generate a
10% crude homogenate, each scrapie-infected brain was homog-
enized in 10 volumes (w/v) of PBS and centrifuged at 2006g for
30 s. The supernatant fraction containing PrP
Sc was divided into
aliquots and stored at 270uC. To generate a PrP
0/0 brain
Author Summary
Over the past two decades, various investigators have
observed that heterozygous animals possessing two
different forms of the gene encoding the prion protein
(PrP) are more difficult to infect with some strains of
infectious prions than homozygous animals possessing
only the most commonly occurring form of the gene
encoding PrP for that species. In 1995, it was hypothesized
that the inhibition of prion infection in heterozygous
animals might be caused by competition between the two
different types of PrP molecules for binding to a common
cofactor required for prion propagation, provisionally
named ‘‘protein X,’’ through a specific portion of the PrP
molecule. Here, we report that mixing different purified
PrP molecules together in test tube reactions lacking
accessory proteins can also interfere with prion propaga-
tion. We also found that some mutations of the putative
protein X binding site do not inhibit the formation of
hamster prions in chemical reactions. Our work suggests
that different PrP molecules most likely compete for
binding to newly formed prions rather than an accessory
protein cofactor, and argues against the existence of
protein X.
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0/0 mouse was first subjected to intracardiac
perfusion with PBS, 5 mM EDTA. The brain was removed and
Dounce homogenized in 5 ml PBS plus Complete
TM protease
inhibitors in order to generate a final homogenate concentration of
10% w/v. The homogenate was centrifuged at 10006g for 30 sec
and the supernatant fraction was divided into aliquots and stored
at 270uC.
Serial protein misfolding cyclic amplification (sPMCA)
Serial PMCA propagation experiments, adapted from Castilla et
al. [38], were performed as previously described [11], except using
both semi-purified CHO-expressed PrP and purified brain-derived
HaPrP
C substrates. All reactions containing MoPrP substrate were
supplemented with 2.5% PrP
0/0 brain homogenate. One hundred
microliter reactions containing HaPrP substrate were either
supplemented with 2.5% PrP
0/0 brain homogenate or 20 mg/ml
synthetic poly(A) RNA. In the experiments testing the ability of
mutant PrP to inhibit wild type PrP
C propagation, equal volumes
of each PrP preparation were combined in the reactions. In the
control reactions containing only wild type PrP
C, an equal volume
of cobalt IMAC elution buffer [20 mM MES pH 6.4, 150 mM
imidazole (in MOPS pH 7.0, 150 mM NaCl), 150 mM NaCl, 1%
Triton-X 100] was combined with the PrP. In pre-incubation
experiments, a master reaction mix containing wild type HaPrP
C
was pre-incubated with poly(A) RNA for 20 min at 37uC, or
Sc237 template seed for 30 min at 37uC, both with shaking at
750 rpm in an Eppendorf Thermomixer, prior to addition of the
Q172R mutant HaPrP. All propagation reactions described above
were seeded on the first round of propagation with 10 ml 0.1%
crude scrapie-brain homogenates diluted in PBS plus 1% Triton-
X 100. In cross-seeding experiments, wild type and mutant CHO-
expressed PrP template seed was derived from the 5
th round of an
sPMCA propagation reaction originally seeded with 10 ml 0.1%
Sc237 scrapie-brain homogenate in the first round.
Supplemental methods
Additional experimental details are provided in Text S1.
Results
sPMCA propagation and infectivity of CHO-expressed PrP
molecules
To study the properties of dominant negative mutant PrP
molecules in vitro we began by expressing wild type mouse and
hamster PrP
C in CHO cells, which do not express detectable levels
of endogenous HaPrP
C protein [41]. Comparison of CHO-
expressed PrP
C molecules to brain-derived PrP
C by SDS-PAGE
revealed that the PrP
C expressed in CHO cells migrated between
26 and 43 kDa, a broader electrophoretic mobility pattern than
brain-derived PrP
C, which migrated between 26 kDa and
,37 kDa (Figure S1, lane 1 vs. 2–5 and lane 6 vs. 7–10).
Deglycosylation of CHO-expressed MoPrP
C with peptide-N-
glycosidase F (PNGase F) revealed that the increase in apparent
molecular weight was due to more extensive glycosylation, as the
core polypeptide of CHO-expressed and brain-derived MoPrP
C
migrated equivalently on an SDS-PAGE gel (data not shown). We
partially purified the mouse and hamster PrP
C from CHO cells by
cobalt-affinity column chromatography for use as sPMCA
substrates. We first conducted three-rounds of serial propagation
reactions using CHO-expressed mouse PrP
C originally seeded
with crude RML murine scrapie brain homogenate and
reconstituted with PrP
0/0 brain homogenate, which contains
cofactors that facilitate the conversion of brain-derived HaPrP
C in
sPMCA reactions [42] (Figure 1A). The results show that MoPrP
C
was efficiently converted and propagated in this reaction,
indicating that MoPrP
C expressed in CHO cells is a competent
substrate for in vitro conversion into a protease-resistant and
autocatalytic form of PrP (Figure 1A, top blot).
We also conducted three-rounds of serial propagation reactions
using the CHO-expressed hamster PrP
C substrate seeded with
crude Sc237 hamster brain homogenate and supplemented with
PrP
0/0 brain homogenate (Figure 1C). The results show that
HaPrP
C was efficiently converted and propagated in this reaction,
indicating that HaPrP
C expressed in CHO cells is also a
competent substrate for in vitro conversion into autocatalytic PrP
(Figure 1C, top blot). In a separate reaction we carried out a seeded
15-round sPMCA propagation reaction with CHO-expressed wild
type HaPrP
C substrate in order to generate a sample containing
autocatalytic HaPrPres, which was beyond limiting dilution of the
original scrapie template. To determine whether this HaPrPres
was infectious, the sample from round 15 of the propagation
reaction was intracerebrally inoculated into wild type hamsters. All
of the inoculated hamsters (6/6) developed clinical scrapie with a
mean incubation time of 141617 days, whereas hamsters
inoculated with a buffer control remain healthy to date (0/5)
.380 days post-inoculation. The brains of hamsters inoculated
with CHO-derived PrP
Sc displayed spongiform degeneration and
PrP deposition consistent with the diagnosis of scrapie (Figure 2).
The vacuolation and PrP deposition profiles of the hamsters
inoculated with Sc237-seeded, CHO-derived PrP
Sc were very
similar to hamsters inoculated with Sc237-seeded brain-derived
PrP
Sc (Figure S2A and B).
sPMCA propagation of mutant mouse PrP molecules
reconstituted with brain homogenate
In order to test whether the MoPrP mutants Q171R, V214K,
and Q218K retain dominant negative activity in vitro,w e
conducted serial protein-misfolding cyclic amplification (sPMCA)
propagation assays using partially purified CHO-expressed MoPrP
substrate molecules. These sPMCA reactions were seeded on day
0 with RML mouse prions, and reconstituted with Prnp
0/0 brain
homogenate in order to provide a source of potential brain
chaperones, including the putative ‘‘protein X’’ (Figure 1A).
Under these conditions, the Q171R, V214K, and Q218K MoPrP
substrates all failed to undergo conversion, in contrast to the
control wild type MoPrP substrate, which did form autocatalytic
MoPrPres. Given these results, we were interested to know
whether any of the negative MoPrP mutants could inhibit the in
vitro conversion of wild type MoPrP
C in trans. To test this, we
conducted seeded sPMCA propagation reactions containing both
wild type and mutant MoPrP substrates (Figure 1B). As
demonstrated in our previous experiment, wild type MoPrP
C
alone is converted into autocatalytic MoPrPres during serial
propagation (Figure 1B, lanes 3–5). When either the Q171R or
Q218K MoPrP mutant was also added to the reaction, conversion
of the wild type MoPrP
C substrate was completely abolished,
indicating that both of these MoPrP mutants act as dominant
negative substrates in vitro (Figure 1B, lanes 9–11, top and bottom
blots). In contrast, the V214K MoPrP mutant, which did not act as
a dominant inhibitor in ScN2a cells [14], also did not inhibit the
conversion of wild type MoPrP
C (Figure 1B, lanes 9–11, second blot).
We also tested the MoPrP V214I mutant in parallel assays.
Unlike the negative MoPrP mutants tested, V214I is capable of
forming PrPres in ScN2a cells [14]. Correspondingly, we found
that MoPrP V214I is an efficient substrate for RML-seeded
sPMCA reactions (Figure 1A). Thus, the results for RML-seeded
sPMCA propagation assays utilizing CHO-expressed substrates
(Figure 1A and B) correlate completely with the previously
Trans-Dominant Prion Inhibition
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negative MoPrP mutants tested [14].
sPMCA propagation of mutant hamster PrP molecules
reconstituted with brain homogenate
Previous studies of dominant negative PrP mutants in prion-
susceptible cultured mouse cell lines were restricted to the mouse
prion strains RML and 22L [14,15,43,44]. To study the generaliz-
ability of these results and to examine the structure-function
relationships of dominant negative PrP mutants in a different rodent
species and prion strain, we utilized our CHO cell expression system
and sPMCA to study these mutations in hamster PrP.
We were curious to know whether dominant negative properties
of MoPrP mutants would be conferred to HaPrP with
corresponding mutations. We began by generating CHO cell
lines stably expressing the HaPrP mutants Q172R, T215K, and
Q219K which correspond to the MoPrP dominant negative
mutants Q171R, Q214K, and Q218K, respectively [14]. The
SDS-PAGE electrophoretic mobility patterns of these HaPrP
molecules were very similar to wild type HaPrP
C expressed in
CHO cells (Figure S1, lanes 7–10). In general, we also observed
that the HaPrP mutant T215K was enriched for the mono-
glycosylated and unglycosylated isoforms relative to the wild type,
Q172R, and Q219K HaPrP constructs, though the degree of this
glycoform difference varied between individual preparations
(Figure S1, lane 9 vs. 7,8, and 10).
To determine if the HaPrP mutants, Q172R, T215K, and
Q219K, which correspond to the dominant negative MoPrP
mutants Q171R, Q214K, and Q218K, respectively, could be
converted into autocatalytic HaPrPres in vitro we conducted
Figure 1. sPMCA propagation with CHO-expressed PrP substrates and Prnp
0/0 brain homogenate. (A) Reactions containing either wild
type or mutant mouse (Mo) PrP substrate alone were originally seeded with RML scrapie brain homogenate and propagated for three rounds of
sPMCA. (B) Reactions containing either wild type MoPrP
C substrate alone (2Mutant, lanes 2–5) or in combination with either Q171R, V214I, V214K, or
Q218K MoPrP mutant substrates at approximately equimolar concentrations (+Mutant, lanes 8–11), as indicated, were subjected to three rounds of
serial propagation. (C) Reactions containing either wild type or mutant hamster (Ha) PrP substrate alone were originally seeded with Sc237 scrapie
brain homogenate and propagated for three rounds of sPMCA reconstituted with Prnp
0/0 brain homogenate. (D) Reactions containing either wild
type HaPrP substrates alone (2Mutant, lanes 2–5) or in combination with either Q172R, T215K, or Q219K HaPrP mutant substrates at approximately
equimolar concentrations (+Mutant, lanes 8–11), as indicated, were subjected to three rounds of serial propagation. An arrowhead demarks the
,25 kDa PK-resistant T215K HaPrP species. All reactions were reconstituted with Prnp
0/0 brain homogenate. In all blots, a sample containing wild
type or mutant PrP substrate not subjected to proteinase K digestion is shown in the lanes preceding the corresponding PK-digested samples as a
reference for comparison of electrophoretic mobility (2PK PrP, WT, or Mut). All other samples were subjected to limited proteolysis with proteinase K
(25 mg/ml for 30 min. for mouse, 50 mg/ml for 1 hr. for hamster) at 37uC( +PK).
doi:10.1371/journal.ppat.1000535.g001
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partially purified from CHO cells reconstituted with Prnp
0/0 brain
homogenate (Figure 1C, bottom three blots) [14]. Q172R HaPrP
substrate failed to undergo conversion, in contrast to T215K and
Q219K HaPrP mutants, which did form autocatalytic HaPrPres.
Notably, unlike wild type and Q219K HaPrP substrates, the
protease resistant pattern of the T215K HaPrP mutant included a
,25 kDa species which is not formed during conversion of the
other two constructs (Figure 1C, arrowhead).
As in our previous MoPrP experiments, we wanted to
investigate if the HaPrP mutants Q172R, T215K, and Q219K
could inhibit the conversion of wild type HaPrP. To test this, we
conducted seeded sPMCA propagation reactions containing both
wild type and mutant HaPrP substrates (Figure 1D). As
demonstrated in our previous experiment, wild type HaPrP
C
substrate alone was converted into autocatalytic HaPrPres in serial
propagation reactions supplemented with Prnp
0/0 brain homog-
enate (Figure 1C, lanes 3–5, all blots). Strikingly, when Q172R
HaPrP substrate was added to the reaction, conversion of wild
type HaPrP
C substrate was completely abolished, even though
wild type HaPrP
C was present in molar excess (Figure 1D, lanes 9–
11, top blot). In contrast, in reactions containing both wild type
HaPrP
C substrate and either T215K or Q219K HaPrP substrate,
autocatalytic HaPrPres was still formed (Figure 1D, lanes 9–11,
lower blots). While these results do not indicate if T215K and
Q219K HaPrP can inhibit the conversion of CHO-expressed wild
type HaPrP
C, we later found that these mutants can inhibit the
conversion of brain-derived HaPrP
C (see below).
sPMCA propagation of mutant PrP molecules stimulated
by poly(A) RNA
A hypothesized mechanism for the properties of dominant
negative PrP mutants is that they sequester protein X, a molecule
proposed to be required for prion conversion [13,14]. It was
thought that mutations in these PrP molecules increase their
affinity for binding protein X, relative to wild type PrP
C.W e
sought to investigate this proposed mechanism by conducting
prion propagation reactions using the sPMCA assay. To do this we
carried out serial propagation reactions containing HaPrP
substrate and poly(A) RNA instead of Prnp
0/0 brain homogenate.
We have previously demonstrated that sPMCA propagation
reactions supplemented with synthetic homopolymeric poly(A)
RNA can facilitate the formation of native hamster prions [11].
Using sPMCA, we were able to test whether dominant negative
mutations in PrP could affect the ability of poly(A) RNA to
stimulate in vitro conversion.
We first conducted three-rounds of serial propagation reactions
seeded with crude Sc237 brain homogenate and supplemented
with poly(A) RNA (Figure 3A). As in the reactions supplemented
with brain homogenate, Q172R HaPrP substrate failed to undergo
conversion, in contrast to T215K and Q219K HaPrP substrate,
which formed autocatalytic HaPrPres (Figure 3A, bottom three blots).
These results indicate that the inability of Q172R HaPrP substrate
to undergo conversion is not due to a factor present in brain
homogenate, unless that factor is mimicked by, or is itself poly(A)
RNA.
We next examined whether Q172R, T215K, and Q219K
HaPrP substrate could inhibit the conversion of wild type HaPrP
C
substrate in reactions supplemented with poly(A) RNA. Again, as
in reactions supplemented with brain homogenate, when sub-
stoichiometric amounts of Q172R HaPrP substrate was added to
the reaction, conversion of the wild type HaPrP
C substrate was
abolished (Figure 3B, lanes 9–11, top blot).
As it is possible that the ability of the mutant HaPrP molecules
to undergo in vitro conversion could be dependent upon, or affected
by, the strain of scrapie used to seed the propagation reaction, we
Figure 2. Neuropathology of hamsters infected with prions derived from CHO-expressed PrP substrate. Representative histological
fields of the brainstem region in control animals and animals inoculated with CHO-expressed in vitro-generated PrP
Sc molecules. Top row: normal 166
day old Syrian golden hamster, mock inoculated with day 15 sPMCA propagation reaction containing the cobalt-purified fraction from untransfected
CHO cells. Bottom row: terminally ill hamster inoculated with Sc237-seeded day 15 sPMCA reaction containing cobalt-prepared PrP
C expressed from
CHO cells. Both reactions were seeded on day 0 with 0.01% Sc237-infected hamster brain homogenate. Hemotoxylin and eosin (H&E) and PrP
immunohistochemical (3F4 antibody) staining are shown for each group. (Scale bar, 50 mm.)
doi:10.1371/journal.ppat.1000535.g002
Trans-Dominant Prion Inhibition
PLoS Pathogens | www.plospathogens.org 5 July 2009 | Volume 5 | Issue 7 | e1000535Figure 3. sPMCA propagation with Hamster PrP substrates and synthetic poly(A) RNA. (A) Reactions containing either wild type or mutant
HaPrP substrate alone were originally seeded with Sc237 scrapie brain homogenate and propagated for three rounds of sPMCA. (B) Reactions
containing either wild type HaPrP
C alone (2Mutant, lanes 2–5) or in combination with either Q172R, T215K, or Q219K HaPrP mutant substrates at
,1:2 (Mut:WT) ratio (+Mutant, lanes 8–11), as indicated, were subjected to three rounds of serial propagation. All reactions were supplemented with
synthetic poly(A) RNA. In all blots, a sample containing wild type or mutant HaPrP substrate not subjected to proteinase K digestion is shown in the
lane(s) preceding the corresponding PK-digested samples as a reference for comparison of electrophoretic mobility (2PK PrP, WT, or Mut). All other
samples were subjected to limited proteolysis with 50 mg/ml proteinase K for 1 hr at 37uC( +PK).
doi:10.1371/journal.ppat.1000535.g003
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scrapie strain instead of the Sc237 strain (Figure S3). In this
experiment we observed again that wild type HaPrP substrate was
successfully propagated but Q172R HaPrP substrate failed to
undergo conversion (Figure S3, top two blots). Likewise, T215K and
Q219K HaPrP substrate propagated, though conversion was
much less as compared to wild type HaPrP substrate conversion
(Figure S3 bottom blots vs. top).
To test whether mutant PrP molecules might convert slowly into
PrPres molecules, and whether mutant PrP might prolong the
kinetics of WT PrPres formation, we performed sPMCA reactions
in which we increased the duration of each individual propagation
round. These experiments showed that purified Q172R HaPrP
substrate did not form PrPres after 364 day propagation rounds in
reactions supplemented with poly(A) RNA (Figure S4, lanes 13–16,
bottom blot). Similar results were obtained with Q171R, V214K,
and Q218K MoPrP substrates in sPMCA reactions supplemented
with Prnp
0/0 brain homogenate (data not shown). The results also
indicate that the inhibition of WT HaPrPres formation by Q172R
HaPrP was also unaffected by increasing the duration of the
propagation rounds to 4 days (Figure S4, lanes 8–11, bottom blot).
Biochemical characterization of mutant PrP molecules
expressed in CHO cells
Given the unexpected results that the T215K HaPrP, and
Q219K HaPrP mutants could form autocatalytic PrPres products in
sPMCA reactions, we wanted to confirm that these results were not
due to any abnormal cellular processing of the expressed PrP
molecules. Native, brain-derived PrP
C is normally trafficked to the
plasma membrane where it is attached to the outer leaflet via a GPI
anchor [45]. To be certain our HaPrP expressed in CHO cells were
properly trafficked to the surface of the cell, we treated each cell line
with phosphatidylinositol-specific phospholipase C (PI-PLC), an
enzyme which cleaves the linkage between the GPI and protein
moieties of GPI-anchored proteins, releasing the protein into the
extracellular environment. In cell lines not treated with PI-PLC,
wild type and mutant HaPrP were detectable in CHO cell lysates
with little to none detected in PI-PLC incubation media (Figure S5,
lane 1 vs. 2), demonstrating that the expressed HaPrP molecules are
normally associated with the CHO cells and not secreted into the
extracellular environment. In contrast, upon treatment of the cell
lines with PI-PLC, the majority of HaPrP was detected in the media
and not in the cell lysate (Figure S5, lanes 3 vs. 4), indicating that the
HaPrP expressed in these lines is attached to the outside of the
plasma membrane as the GPI anchor was accessible to cleavage by
PI-PLC. We previously reported that treatment of PrP
C with PI-
PLC results ininefficientimmunodetectionof PrP
C bound to PVDF
membrane [46]. This phenomenon likely explains the overall
decreased detection of HaPrP in the cell lines treated with PI-PLC
relative to the untreated cells (Figure S5, lane 2 vs. lanes 3–4
combined). These results show that, similar to native HaPrP
C,
CHO-expressed wild type and mutant HaPrP stably expressed in
CHOcellsareproperlytraffickedandattachedtothe outerleaflet of
the plasma membrane.
We next tested whether the HaPrP expressed in our CHO cells
was detergent soluble under non-denaturing conditions, a
biochemical characteristic of brain-derived PrP
C [47] (Figure
S6). CHO cells lines expressing wild type and mutant HaPrP were
solubilized in detergent and subjected to ultracentrifugation in
order to separate the soluble and insoluble fractions. The majority
of each HaPrP construct was recovered in the detergent-soluble
supernatant fraction with little or no HaPrP in the detergent-
insoluble pellet fraction (Figure S6, lane 2 vs. lane 3). Together these
data indicate that HaPrP expressed in our CHO cell lines
undergoes cellular processing and trafficking in a manner similar
to native, brain-derived PrP
C.
Dose-dependent inhibition of brain-derived PrP
C
substrate by mutant PrP molecules in trans
While it was clear the Q172R HaPrP substrate could inhibit the
conversion of wild type HaPrP
C substrate, we still could not
conclude whether T215K and Q219K HaPrP substrates possess
the same dominant negative properties. Our HaPrP substrate
expressed in CHO cells has a higher relative molecular weight as
compared to brain-derived HaPrP
C; thus, the molecular weight of
protease-resistant PrP derived from the conversion of these
different PrP substrates should also be distinguishable by SDS-
PAGE. We decided to exploit this biochemical difference between
HaPrP substrates to determine if T215K and Q219K HaPrP
substrate act as dominant negatives. We conducted seeded
sPMCA propagation reactions containing both immunopurified
brain-derived wild type HaPrP
C and mutant HaPrP substrates
supplemented with poly(A) RNA (Figure 4). Consistent with
previous studies, brain-derived wild type HaPrP
C substrate was
converted into autocatalytic HaPrP
Sc in serial propagation
reactions supplemented with poly(A) RNA (Figure 4, lanes 3–5,
all blots). When Q172R HaPrP substrate was added to the reaction,
conversion of brain-derived wild type HaPrP
C substrate was
blocked (Figure 4, lanes 9–11, top blot).
In reactions containing both wild type HaPrP
C substrate and
either the T215K or Q219K HaPrP substrate, autocatalytic
HaPrPres was still formed (Figure 4, lanes 9–11, lower middle blots).
However, the molecular weight of the HaPrPres formed in these
reactions corresponded to the weight of T215K and Q219K
HaPrPres, and not brain-derived HaPrP
Sc (predicted mobility
shown with arrowheads). The protease resistant band correspond-
ing to brain-derived HaPrP
Sc was not present in reactions
containing both wild type HaPrP
C and mutant HaPrP substrates
(Figure 4, lanes 9–11 vs. 3–5). Similar to Q172R, this finding shows
T215K and Q219K HaPrP substrate can inhibit the conversion of
brain-derived wild type HaPrP
C substrate and, therefore, act as
dominant negatives in vitro.
As the concentration of the mutant HaPrP substrate in these
reactions was greater than brain-derived HaPrP
C substrate, we
wanted to test whether conversion could be inhibited at lower
mutant PrP substrate concentrations. In order to investigate this we
conducted a propagation reaction containing purified brain-derived
HaPrP
C substrate and a sub-stoichiometric concentration of
Q219K HaPrP substrate (Q219K Low) (Figure 4, bottom blot).
Interestingly, under these conditions both wild type HaPrP
C and
Q219K HaPrP substrates were converted into autocatalytic,
protease-resistant HaPrP as indicated by two distinct bands
(Figure 4, lanes 9–11, bottom blot). This finding demonstrates that
inhibition of wild type PrP
C conversion by Q219K occurs in a dose-
dependent manner; at stoichiometrically higher doses Q219K PrP
inhibits conversion but at stoichiometrically lower doses, wild type
PrP
C still occurs. Furthermore, in this case, trans-dominant
interference appears to be asymmetrical; Q219K appears to block
conversion of WT PrP (Figure 4, lanes 9–11, 4th blot from top, see
absence of band at the arrowhead), but not vice versa (Figure 4, lanes
9–11, bottom blot, see presence of band above the arrowhead).
Dominant negative inhibition with purified PrP
molecules
In order to exclude the possibility that an external molecule that
co-purifies with mutant PrP substrate is required for dominant
negative inhibition we conducted propagation reactions containing
Trans-Dominant Prion Inhibition
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C and purified Q172R
(Q172R Pure) HaPrP substrate (Figure 4). As in the reactions
containing partially purified Q172R HaPrP substrate, fully purified
Q172R HaPrP substrate still maintained the ability to inhibit the
conversion of purified HaPrP
C substrate (Figure 4, lanes 9–11).
Pre-incubation of PrP with poly(A) RNA and scrapie
template
As there are several possible explanations for how Q172R
HaPrP exerts its dominant negative properties, we sought to
examine more closely the mechanism by which Q172R HaPrP-
mediated inhibition occurs. One possible mechanism is that
compared to wild type HaPrP
C, Q172R HaPrP has increased
affinity for binding poly(A) RNA, a necessary cofactor for
conversion in this in vitro assay. To test whether Q172R HaPrP
might interfere with the interaction between poly(A) RNA and
wild type HaPrP
C, we conducted a serial propagation reaction in
which CHO-expressed wild type HaPrP
C substrate was allowed to
pre-incubate with poly(A) RNA prior to addition of the Q172R
HaPrP substrate to the reaction (Figure 5, top blot). We previously
determined that our wild type HaPrP
C rapidly (,15 min) binds to
immobilized poly(A) RNA (data not shown) and therefore, under
the tested pre-incubation conditions, the wild type HaPrP
C
substrate should have sufficient time to physically interact with
poly(A) RNA before encountering Q172R HaPrP substrate. As
previously demonstrated, when wild type and Q172R HaPrP
substrates are combined simultaneously in the reaction, conversion
of wild type HaPrP
C substrate is inhibited (Figure 4). When wild
type HaPrP substrate was allowed to incubate with poly(A) RNA
before the addition of Q172R HaPrP substrate and Sc237 seed,
conversion of wild type HaPrP
C substrate was still inhibited
(Figure 5, +Pre-incubation, lanes 10–12). Assuming that the wild type
HaPrP
C substrate interacted with poly(A) RNA during the pre-
incubation, this finding indicates that Q172R HaPrP substrate
does not block conversion of wild type HaPrP
C substrate by
sequestering the required cofactor, poly(A) RNA.
Another potential mechanism of Q172R HaPrP dominant
negative inhibition is that, during the first round of sPMCA, this
mutant binds to and sequesters the Sc237 scrapie template seed,
making it inaccessible to wild type HaPrP
C. Alternatively, Q172R
HaPrP might bind directly to wild type HaPrP
C to physically block
it from interacting with the scrapie seed. In either scenario, if the
scrapie seed is physicallyinaccessible to wild typeHaPrP
C, then lack
of interaction with this template could explain the inhibition of
Figure 4. Inhibition of hamster brain PrP
C conversion by dominant negative mutant PrP. Reactions containing either purified brain-
derived HaPrP
C alone (2Mutant, lanes 2–5) or in combination with either Q172R, immunopurified Q172R (Q172R Pure), T215K, or different
concentrations of Q219K HaPrP mutant substrates (+Mutant, lanes 8–11), as indicated, were subjected to three rounds of serial propagation. Q172R
Pure was tested at ,1:2 (Mut:WT) ratio; Q172R Low was tested at ,1:5 ratio; and all other conditions were tested at ,5:1 ratio. In each blot, an
arrowhead demarks the expected mobility of the ,27–30 kDa PK-resistant brain-derived PrP
Sc species. All reactions were supplemented with
synthetic poly(A) RNA. In all blots, a sample containing wild type or mutant HaPrP substrate not subjected to proteinase K digestion is shown in the
lane(s) preceding the corresponding PK-digested samples as a reference for comparison of electrophoretic mobility (2PK WT or Mut). All other
samples were subjected to limited proteolysis with 50 mg/ml proteinase K for 1 hr at 37uC( +PK).
doi:10.1371/journal.ppat.1000535.g004
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HaPrP
C from interacting with the scrapie seed, we performed a
serial propagation reaction in which CHO-expressed wild type
HaPrP
C substrate was pre-incubated with both poly(A) RNA and
the Sc237 template seed (Figure 5, bottom blot). Again, without pre-
incubation wild type HaPrP
C substrate failed to undergo conversion
when added to the reaction simultaneously with the Q172R HaPrP
substrate (Figure 5, bottom blot, lanes 4–6). Likewise, pre-incubating
wild type HaPrP
C substrate with both Sc237 seed and poly(A) RNA
before addition of Q172R HaPrP substrate to the reaction failed to
rescue conversion (Figure 5, bottom blot, lanes 10–12). This result
suggests that Q172R HaPrP inhibits prion formation by a
mechanism other than preventing the interaction of wild type
HaPrP
C with the Sc237 scrapie seed. However, a limitation of this
experiment is that the initial binding of PrP
C to PrP
Sc might be
weak, accompanied by a high dissociation rate. In this scenario, pre-
incubation of mutant PrP molecules with the Sc237 scrapie seed
might not prevent the template PrP
Sc molecules from subsequently
interacting with wild type PrP
C molecules.
Cross-seeding of wild type and mutant PrP molecules
Our finding that dominant negative inhibition of prion formation
does not appear to involve the scrapie template or an external
cofactor supports a model of inhibition mediated by direct
interaction between PrP molecules. One possibility is that dominant
negative PrP mutants cannot act as templates for conversion of wild
type PrP. Therefore, if a mutant PrP molecule is integrated into a
growing oligomer of converted wild type PrP, it could block further
wild type PrP conversion because it lacks templating activity. In
order to test whether dominant negative PrP mutants can act as a
template for conversion of wild type PrP we conducted sPMCA
propagation reactions containing wild type and mutant HaPrP
substrates which were seeded with CHO-derived wild type or
mutant HaPrPres (Figure 6). As expected, CHO-derived wild type
HaPrPres was able to act as a template for the conversion of wild
type, T215K, and Q219K HaPrP substrates (Figure 6A, lanes 3–5).
Interestingly, T215K and Q219K HaPrPres were also able to act as
a template for the conversion of wild type HaPrP
C substrate
(Figure 6B, top and lower middle blot, lanes 3–5). As dominant negative
HaPrP mutants retain the ability to seed the conversion of wild type
HaPrP
C substrate, they must inhibit prion formation by a
mechanism other than simply lacking templating activity.
Discussion
Infectious prions produced from CHO-expressed PrP
substrate
In this study we report the development of a novel system for
rapidly studying the effect of PrP mutations on prion propagation
in vitro. Specifically, this system allows for characterizing the
biochemical properties of mutant PrP while measuring the ability
of mutant PrP to undergo conformational conversion to generate
PrPres in vitro. This technique utilizes Flp-In CHO cells to generate
cultured lines stably expressing PrP. Unlike bacterial expression
systems, CHO cells process PrP in a more native manner that
allows for the addition of a GPI anchor and N-linked carbohydrate
groups. We found that PrP expressed in CHO cells displayed an
aberrant glycosylation profile relative to native, brain-derived
PrP
C. However, despite this difference in processing, we showed
that partially purified wild type HaPrP
C and MoPrP
C substrates
expressed in CHO cells could be converted to a protease-resistant
and self-propagating PrP conformation using the sPMCA assay.
The PrPres formed during PMCA was as equally resistant to PK
treatment as PrP
Sc formed in sPMCA using brain-derived PrP
C
substrates [11,12]. In addition, we found that CHO-expressed
HaPrP
C substrate could be converted in vitro to HaPrP
Sc, which
was autocatalytic and infectious to wild type hamsters, with
associated strain properties indistinguishable from Sc237-seeded,
sPMCA-generated, brain-derived HaPrP
Sc molecules. The 140
day prion incubation time produced by Sc237-seeded, CHO-
expressed, sPMCA-generated HaPrP
Sc molecules was significantly
longer than that produced by native Sc237 prions, and slightly
shorter than that produced by Sc237-seeded, brain-derived
HaPrP
Sc molecules [11,38]. Based on the previously measured
Figure 5. Inhibition of hamster PrP
C conversion following hamster PrP
C substrate pre-incubation with poly(A) RNA and/or Sc237.
Western blots showing Sc237-seeded sPMCA propagation reactions containing wild type, Q172R HaPrP substrates, and synthetic poly(A) RNA.
Reactions containing both CHO-expressed wild type HaPrP
C and the Q172R mutant HaPrP substrates at ,1:2 (Mut:WT) ratio (lanes 3–6 and 9–12)
were subjected to three rounds of serial propagation. Wild type HaPrP
C substrate was either pre-incubated (+Pre-incubation) or not (2Pre-incubation)
with poly(A) RNA alone (top blot) or in combination with the Sc237 scrapie seed (bottom blot), as indicated, prior to addition of the Q172R HaPrP
substrate and other components to the reaction. In all blots, samples containing recombinant wild type or mutant HaPrP substrate not subjected to
proteinase K digestion are shown as a reference for comparison of electrophoretic mobility (2PK WT or Mut, respectively). All other samples were
subjected to limited proteolysis with 50 mg/ml proteinase K for 1 hr at 37uC( +PK).
doi:10.1371/journal.ppat.1000535.g005
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sPMCA-generated HaPrP
Sc molecules [11] and quantitation of
PrP concentration by serial dilutions on Western blots, we
calculate that the specific infectivity of CHO-derived, sPMCA-
generated HaPrP
Sc molecules is approximately equal to that of a
brain-derived preparation of PrP27-30 molecules. It is not known
why sPMCA-generated HaPrP
Sc molecules exhibit an altered
relationship between titer and incubation time, but studies with
nitrocellulose carriers suggest that sonication may disrupt the size
distribution of infectious HaPrP
Sc molecules [40]. Thus, with these
caveats taken into consideration, our findings show for the first
time that PrP
C expressed in a cultured mammalian cell line can be
used as a substrate for the generation of an infectious prion in vitro.
This indicates that utilizing CHO-expressed PrP
C as an sPMCA
substrate is a powerful approach for studying the molecular
mechanism of prion formation in vitro.
Furthermore, combining PrP expressed in cell culture with the
sPMCA technique provides several advantages over other
methods of studying prion conversion. In cell-based models of
prion propagation, cellular processes such as PrP trafficking and
clearance of PrP
Sc can pose a challenge to study the conversion of
PrP effectively. The system we describe allows for the study of PrP
in the absence of any cellular process that might influence prion
conversion. Many of the cell lines that can propagate prions, such
as mouse N2a cells, express endogenous PrP
C [14,48]. As such,
PrP expressed in these lines must often be tagged in some manner
in order to discriminate it from endogenous PrP
C. This does not
pose a problem in our system because CHO cells do not express
detectable levels of endogenous PrP
C [41]. In addition to studying
PrP mutations, prion strains and species differences can be easily
investigated using this system, providing a versatile and efficient
alternative to studying PrP in cell culture or transgenic mouse
models of prion conversion. However, in implementing this system
in our studies, we are aware that the relationship between PrP and
prion infectivity is complex, and remains poorly understood. Some
disease models have little or no detectable PrP
Sc despite high levels
of prion infectivity [5,6], and the measurement of protease-
resistant PrP
Sc by Western blotting (without amplification) is not as
sensitive as bioassay. In our system, some of these issues are at least
partially mitigated by the use of 3-day sPMCA assays, which are
highly sensitive [49], report upon PrP
Sc autocatalysis in addition to
protease-resistance, and allow time for slowly propagating
reactions between heterologous PrP molecules to adapt confor-
mation. Nonetheless, like all biochemical assays of prion
formation, sPMCA experiments must be used and interpreted
cautiously.
Species-dependent effects of putative protein X binding
site mutation
Previous studies in transgenic mouse and cell-culture models of
prion conversion led to the identification of four residues within
MoPrP which, when mutated singly to basic residues, prevented
prion formation [13,14]. Utilizing PrP expressed in CHO cells, we
found that Q171R, V214K, and Q218K MoPrP substrates could
not be converted into MoPrPres in sPMCA reactions supplement-
ed with Prnp
0/0 brain homogenate, confirming that residues
Q171, V214, and Q218 are also required for the formation of
RML mouse prions in vitro. In contrast, two hamster PrP mutants
(T215K and Q219K), whose corresponding MoPrP homologues
do not support prion formation either in RML-seeded sPMCA
reactions or in the ScN2a cell-culture model, could be readily
converted into self-propagating PrPres in sPMCA reactions driven
by Sc237 hamster scrapie. These opposing results could be due to
either differences in the species of the PrP substrate or the scrapie
strain used to seed the propagation reactions. In either case, the
ability of hamster T215K and Q219K PrP to convert into
autocatalytic PrPres is inconsistent with the hypothesis that these
residues are required to help form a discontinuous binding site for
an accessory catalyst shared among rodent species, such as protein
X. Moreover, the differences in behavior between mouse and
Figure 6. Cross-seeding experiments. (A) Reactions containing
either wild type or mutant HaPrP substrate were originally seeded with
CHO-derived HaPrPres and propagated for three rounds of sPMCA. (B)
Reactions containing either wild type HaPrP
C, T215K, or Q219K HaPrP
substrates (Substrate) were originally seeded with CHO-derived T215K
or Q219K HaPrPres template (Template) and subjected to three rounds
of serial propagation. All reactions were supplemented with synthetic
poly(A) RNA. In all blots, a sample containing wild type or mutant HaPrP
substrate not subjected to proteinase K digestion is shown in the lane(s)
preceding the corresponding PK-digested samples as a reference for
comparison of electrophoretic mobility (2PK PrP or Mut). All other
samples were subjected to limited proteolysis with 50 mg/ml proteinase
K for 1 hr at 37uC( +PK).
doi:10.1371/journal.ppat.1000535.g006
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formation may not be identical between these two species. Indeed,
previous studies have shown that whereas formation of mouse
prions in vitro requires unglycosylated MoPrP
C molecules in the
substrate, unglycosylated HaPrP
C molecules inhibit the formation
of hamster prions in a dose-dependent fashion [39], and that
recombinant hamster and mouse PrP molecules follow different
folding pathways towards amyloid fibril formation [50]. Interest-
ingly, Hizume et al. recently reported that transgenic mice
expressing human PrP E219K were susceptible to human prions
[23]. Therefore, this mutation does not abolish the ability of PrP
molecules from at least two different animal species to act as
substrates for prion formation.
Our studies also showed that residue Q171 in mouse PrP and
the homologous residue Q172 in hamster PrP was required for
prion formation in both species, raising the possibility that this
residue may play a fundamental role in the process of prion
formation in both species.
PrP mutants retain dominant inhibitory activity in vitro
Collectively, the data presented in this manuscript refute the
hypothesisthat proteinX orany otheraccessorycofactor isrequired
for dominant negative inhibition of prion formation. Moreover, the
ability of the Q172R mutant to inhibit hamster prion formation in a
purified system even when WT HaPrP substrate was pre-incubated
with both poly(A) RNA and scrapie template suggests that mutant
PrP inhibits the conversion of WT PrP by blocking a nascent
seeding site (NSS) on newly formed, PMCA-generated PrP
Sc
molecules (Figure 7). Our data also show complete dissociation
between conversion ability and trans-dominant inhibitory activity.
Most notably, we showed that Q219K HaPrP is able both to
convert into PrPres itself and to inhibit the conversion of WT PrP in
trans. Thus, we can conclude that the mechanism of trans-dominant
inhibition does not require a ‘‘negative’’ mutation, i.e. a PrP
molecule that is unable to convert into PrPres itself.
The simplest model that can account for these observations
simultaneously is that the tested PrP mutants directly compete for
binding to the PrP
Sc NSS, regardless of their ability to convert to
PrPres (Figure 7). Because Q172R is able to act as a dominant
negative inhibitor at sub-stoichiometric levels, we reason that this
mutant has the highest affinity for the PrP
Sc NSS amongst the
mutants tested. In contrast, because T215K does not appear to
inhibit conversion of WT PrP in trans, we reason that this mutant
has the lowest affinity for the PrP
Sc NSS amongst the mutants
tested. Because Q219K HaPrP only blocks conversion of WT
HaPrP when the concentration of mutant protein is in molar
excess, we reason that Q219K HaPrP (and by extension, the
homologous Q218K MoPrP mutant) has lower affinity for the
PrP
Sc NSS than the Q172R. We can also deduce that Q219K
HaPrP has a higher affinity for the PrP
Sc NSS than WT HaPrP
because WT PrP does not dominantly inhibit the conversion of
Q219K PrP, even when the concentration of WT PrP exceeds that
of Q219K. Taken together, we propose the following rank order of
affinity for the PrP
Sc NSS (numbering based on mouse PrP):
Q171R.Q218K.WT$V214K (Figure 7).
It is interesting to speculate about the possible mechanism
responsible for the high affinity of the Q171R mutant. Residue
Q171 resides within a short loop that connects b2 strand and a2
helix (residues 170–174), which has been implicated in the
transmission barrier between animal species and in the de novo
Figure 7. Model of trans-dominant inhibition of prion formation. This diagram illustrates the proposed model of competition between
various PrP substrate molecules for binding to a nascent seeding site on newly formed PrP
Sc molecules. Legend: Sc=PrP
Sc; WT=wild type PrP
C;
mutant PrP molecules labeled according to residue numbering for mouse PrP. The relative affinities of various PrP molecules for the nascent seeding
site on the growing PrP
Sc polymer are indicated schematically by the length and curvature of the cartoon protrusion, which is meant to represent the
NSS binding domain, and which likely includes the residue 170–174 loop domain.
doi:10.1371/journal.ppat.1000535.g007
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high affinity of Q171R suggests that this loop may also be the
major PrP
C epitope recognized by the PrP
Sc NSS. Q171R may
bind with higher affinity than WT PrP
C because the PrP
Sc NSS
may contain an anionic contact point, either due to exposure of a
negatively charged PrP residue, or of a physically embedded
anionic cofactor [12]. Both the high affinity of the Q171R mutant
for the PrP
Sc NSS and the ability of the Q171R mutation to
prevent conversion of both hamster and mouse PrP molecules (as
described in the preceding section) lend support to the hypothesis
proposed by Sigurdsson et al. that the loop region which contains
this residue plays a vital role in prion formation [51].
Using an in vitro fibril formation technique, Lee et al. showed that
mixtures of bacterially-expressed, recombinant WT and Q218K
MoPrP molecules displayed slower polymerization kinetics than
samples containing either WT or Q218K MoPrP alone [30]. It is
likely that heteropolymer destabilization also contributes to the
ability of trans-dominant PrP mutants to inhibit the sPMCA-
facilitated propagation of mammalian prions, under conditions
that permit both mutant and WT PrP molecules to bind to and
incorporate into the growing PrP
Sc polymer. However, the process
of heteropolymer destabilization alone cannot fully explain the
results of our studies, particularly the asymmetrical interaction
between WT and Q219K HaPrP (i.e., Q219K completely inhibits
conversion of WT HaPrP when present in molar excess, but not
vice versa, indicating that WT PrP is excluded from co-polymerizing
with Q219K PrP when the mutant is present in excess (Figure 4)).
Hence, we propose that trans-dominant inhibition potentially
occurs at two sequential stages: (1) initially, mutant and WT PrP
molecules compete to bind at the PrP
Sc NSS, and then (2) if both
mutant and WT PrP molecules are able to bind to and incorporate
into a growing PrP
Sc polymer, the heteropolymer may become
kinetically destabilized.
Using scrapie-infected tissue culture models, other investigators
have previously demonstrated dose-dependent, dominant negative
inhibition by heterologous PrP
C molecules [31,32]. Additional
studies showed that the presence of non-converting, heterologous
PrP
C molecules interfered with the ability of PrP
C molecules
homologous to the PrP
Sc template to acquire protease-resistance in
a cell-free assay using purified components [33]. Interestingly,
radioactive heterologous and homologous PrP
C molecules bound
to the PrP
Sc template equally well, suggesting two alternative
models for heterologous interference [33,53]: (1) in the single site
model, inhibition is proposed to occur primarily by the inhibition
of conversion (rather than binding) of homologous PrP
C substrate
to PrP
Sc by heterologous, non-converting PrP
C molecules; (2) in
the two-site model, it is proposed that heterologous PrP
C
molecules competitively inhibit binding of homologous PrP
C
substrate to a conversion-inducing site on the PrP
Sc template,
while both species of PrP
C molecules are able to bind non-
competitively to a second binding site on PrP
Sc, which does not
influence conversion. It is reasonable to hypothesize that the same
molecular mechanism underlies interference between heterologous
PrP
C molecules and the trans-dominant inhibitory activity of the
‘‘protein X binding site’’ mutants. If that hypothesis is correct,
then it is interesting to note that several results from our study
appear to be incompatible with the single site model; specifically
we identified: (1) convertible PrP mutants that can inhibit
conversion in trans; (2) non-convertible PrP mutants that do not
inhibit in trans; (3) a dominant negative mutant that inhibits at sub-
stoichiometric levels; and (4) asymmetric inhibition between two
convertible PrP
C molecules. These results would be compatible
with the two-site model, in which the NSS would represent the
conversion-inducing site. However, further studies are required to
confirm the hypothesis that the same mechanism mediates the
inhibitory activities of heterologous PrP
C molecules and ‘‘protein
X binding site’’ mutants.
In summary, our results show that protein X is not required to
mediate dominant inhibition of prion propagation in vitro, and
suggest instead that PrP molecules compete for binding to the NSS
of newly formed PrP
Sc molecules. A critical part of the binding
surface appears to be located within the short loop (between b2
strand and a2 helix) of PrP
C recently shown to modulate
spontaneous prion formation [51]. However, the results of
biochemical assays cannot be equated to the genetic control of
prion transmission in vivo, and further studies in living animals will
be required to confirm the physiological basis of dominant
negative inhibition.
Supporting Information
Text S1 Supplemental Methods
Found at: doi:10.1371/journal.ppat.1000535.s001 (0.10 MB
PDF)
Figure S1 Stable expression of PrP molecules in CHO cells.
Western blot showing samples containing either brain-derived
MoPrP
C (lane 1) and HaPrP
C (lane 6) or CHO-expressed wild type,
Q171R, V214K, and Q218K MoPrP (lanes 2–5, respectively) and
wild type, Q172R, T215K, and Q219K HaPrP (lanes 7–10,
respectively). The PrP in all samples was partially purified on a
cobalt-IMAC column before immunoblot detection.
Found at: doi:10.1371/journal.ppat.1000535.s002 (0.29 MB PDF)
Figure S2 Regional neuropathology of hamsters inoculated with
in vitro-generated PrP
Sc molecules. Vacuolation profile scores (A)
and PrP 3F4 immunohistochemistry profiles (B) of animals
inoculated with samples containing PrP
Sc molecules generated in
vitro from Sc237-seeded 15-cycle sPMCA reactions containing
PrP
C (open squares) prepared from stably transfected CHO cells
or (filled circles) isolated from hamster brain. For each, the mean
values (n=6–15 animals/group) are shown 6SEM. Brain regions:
FC, frontal cortex; PC, parietal cortex; H, hippocampus; C,
cerebellum; M, medulla.
Found at: doi:10.1371/journal.ppat.1000535.s003 (0.31 MB
PDF)
Figure S3 sPMCA propagation reactions seeded with the 139H
scrapie strain. Western blots showing sPMCA propagation
reactions containing wild type, Q172R, T215K, or Q219K
mutant HaPrP substrates. Reactions containing either wild type
or mutant HaPrP substrate alone were originally seeded with
139H scrapie brain homogenate and propagated for three rounds
of sPMCA. All reactions were supplemented with synthetic poly(A)
RNA. In all blots, a sample containing wild type or mutant HaPrP
substrate not subjected to proteinase K digestion is shown in the
lanes preceding the corresponding PK-digested samples as a
reference for comparison of electrophoretic mobility (PrP, Mut
2PK). All other samples were subjected to limited proteolysis with
50 mg/ml proteinase K for 1 hr at 37uC( +PK).
Found at: doi:10.1371/journal.ppat.1000535.s004 (0.27 MB
PDF)
Figure S4 Effect of increasing propagation time length on
mutant PrP conversion and inhibition. Reactions containing either
wild type (WT only, lanes 2–5), an equimolar mixture of wild type
and Q172R HaPrP (WT +Mutant, lanes 8–11), or Q172 HaPrP
(Mutant only, lanes 13–16) substrate alone were originally seeded
with Sc237 scrapie brain homogenate and propagated for three
rounds of sPMCA. All reactions were supplemented with synthetic
poly(A) RNA and originally seeded with Sc237 brain homogenate.
Trans-Dominant Prion Inhibition
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blot), 2 days (middle blot), or 4 days (bottom blot). In all blots, a
sample containing wild type or mutant HaPrP substrate not
subjected to proteinase K digestion is shown in the lane(s)
preceding the corresponding PK-digested samples as a reference
for comparison of electrophoretic mobility (2PK WT or Mut). All
other samples were subjected to limited proteolysis with 50 mg/ml
proteinase K for 1 hr at 37uC( +PK).
Found at: doi:10.1371/journal.ppat.1000535.s005 (0.38 MB PDF)
Figure S5 Cell surface localization of HaPrP molecules
expressed in CHO cells. CHO cell lines stably expressing wild
type and mutant HaPrP were treated with (lanes 3 and 4)o r
without (lanes 1 and 2) PI-PLC in order to assess anchorage to the
outer leaflet of the plasma membrane via the GPI anchor.
Following treatment, proteins in the PIPLC incubation media
(Media, lanes 1 and 3) were precipitated, and the cells (Lysate, lanes 2
and 4) were harvested in lysis buffer. PrP was detected in the
precipitated protein and cell lysate samples by Western blotting.
Found at: doi:10.1371/journal.ppat.1000535.s006 (0.32 MB PDF)
Figure S6 Detergent solubility of HaPrP molecules expressed in
CHO cells. CHO cell lines stably expressing wild type and mutant
HaPrP were harvested in lysis buffer containing 0.5% Triton-X
100 and 0.5% DOC. A portion of each cell lysate was removed
(TOT, lane 1), the remainder of each lysate was centrifuged at
100,0006g, and the supernatant and pellet fractions were isolated.
Equivalent amounts of the Total lysates, supernatant (SUP, lane 2)
and pellet (PEL, lane 3) fractions were resuspended in SDS-PAGE
loading buffer and rPrP was detected in each sample by Western
blotting.
Found at: doi:10.1371/journal.ppat.1000535.s007 (0.22 MB PDF)
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